ReIMAGINE represents the first efforts to define prostate cancer risk using the full spectrum of emerging diagnostics (both commercial and academic). The outputs will provide image-based data sets that will replace, or adjust, historical and flawed risk calculators.
Trial registration: ClinicalTrials.gov NCT04060589.
Copyright © 2021. Published by Elsevier B.V.